GRAIL (GRAL) Stock Overview
A commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
GRAL Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
GRAIL, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.56 |
| 52 Week High | US$118.84 |
| 52 Week Low | US$21.80 |
| Beta | 0 |
| 1 Month Change | -2.28% |
| 3 Month Change | -52.49% |
| 1 Year Change | 109.10% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 248.17% |
Recent News & Updates
Recent updates
GRAIL: NHS-Galleri Trial Results Are A Foul Ball, Not A Strikeout
Apr 08
Clinical Trial Setbacks And Reimbursement Delays Will Eventually Support Early Cancer Detection Potential
Catalysts About GRAIL GRAIL focuses on multi cancer early detection through its Galleri screening test and related clinical programs. What are the underlying business or industry changes driving this perspective?
NHS Trial Momentum And Medicare Pathway Will Support Long Term Multi Cancer Screening Adoption
Catalysts About GRAIL GRAIL develops and commercializes Galleri, a blood based multi cancer early detection test aimed at finding cancers at earlier stages. What are the underlying business or industry changes driving this perspective?
Overvaluation Risks And NHS Trials Will Spur Future Resilience
Market optimism may overestimate Galleri's near-term adoption and pricing power due to regulatory, payer, and competitive pressures.GRAIL: Cash Burn And Commercialization Timeline Are Problematic
Jan 22Here's Why We're Watching GRAIL's (NASDAQ:GRAL) Cash Burn Situation
Dec 24
Grail: Lack Of Near Term Catalyst; Market Likely To Lose Interest Soon
Dec 16GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success
Sep 24GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri
Sep 09Shareholder Returns
| GRAL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -13.5% | 1.6% | 3.4% |
| 1Y | 109.1% | 46.8% | 29.7% |
Return vs Industry: GRAL exceeded the US Biotechs industry which returned 41.7% over the past year.
Return vs Market: GRAL exceeded the US Market which returned 25.7% over the past year.
Price Volatility
| GRAL volatility | |
|---|---|
| GRAL Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: GRAL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GRAL's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 910 | Bob Ragusa | grail.com |
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development.
GRAIL, Inc. Fundamentals Summary
| GRAL fundamental statistics | |
|---|---|
| Market cap | US$2.08b |
| Earnings (TTM) | -US$408.35m |
| Revenue (TTM) | US$147.17m |
Is GRAL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRAL income statement (TTM) | |
|---|---|
| Revenue | US$147.17m |
| Cost of Revenue | US$75.86m |
| Gross Profit | US$71.32m |
| Other Expenses | US$479.67m |
| Earnings | -US$408.35m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.95 |
| Gross Margin | 48.46% |
| Net Profit Margin | -277.47% |
| Debt/Equity Ratio | 0% |
How did GRAL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/09 09:20 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GRAIL, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Kyle Mikson | Canaccord Genuity |
| Subhalaxmi Nambi | Guggenheim Securities, LLC |